Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Duodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonism to discontinue insulin in type 2 diabetes: a feasibility study.
van Baar ACG, Meiring S, Smeele P, Vriend T, Holleman F, Barlag M, Mostafavi N, Tijssen JGP, Soeters MR, Nieuwdorp M, Bergman JJGHM. van Baar ACG, et al. Among authors: holleman f. Gastrointest Endosc. 2021 Jul;94(1):111-120.e3. doi: 10.1016/j.gie.2020.12.021. Epub 2020 Dec 24. Gastrointest Endosc. 2021. PMID: 33359437 Free article. Clinical Trial.
Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes.
Nieuwdorp M, Mooij HL, Kroon J, Atasever B, Spaan JA, Ince C, Holleman F, Diamant M, Heine RJ, Hoekstra JB, Kastelein JJ, Stroes ES, Vink H. Nieuwdorp M, et al. Among authors: holleman f. Diabetes. 2006 Apr;55(4):1127-32. doi: 10.2337/diabetes.55.04.06.db05-1619. Diabetes. 2006. PMID: 16567538
Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study: A multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetes.
Swinnen SG, Snoek FJ, Dain MP, DeVries JH, Hoekstra JB, Holleman F. Swinnen SG, et al. Among authors: holleman f. Diabetes Technol Ther. 2009 Nov;11(11):739-43. doi: 10.1089/dia.2009.0044. Diabetes Technol Ther. 2009. PMID: 19905891 Clinical Trial.
A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs.
Swinnen SG, Dain MP, Aronson R, Davies M, Gerstein HC, Pfeiffer AF, Snoek FJ, Devries JH, Hoekstra JB, Holleman F. Swinnen SG, et al. Among authors: holleman f. Diabetes Care. 2010 Jun;33(6):1176-8. doi: 10.2337/dc09-2294. Epub 2010 Mar 3. Diabetes Care. 2010. PMID: 20200301 Free PMC article. Clinical Trial.
Insulin detemir versus insulin glargine for type 2 diabetes mellitus.
Swinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH. Swinnen SG, et al. Among authors: holleman f. Cochrane Database Syst Rev. 2011 Jul 6;2011(7):CD006383. doi: 10.1002/14651858.CD006383.pub2. Cochrane Database Syst Rev. 2011. PMID: 21735405 Free PMC article. Review.
140 results